Searched for
SHARES OF SPARC
Bill Ackman's Pershing Square proposes $64 billion merger deal with Universal Music GroupBill Ackman's Pershing Square proposed a deal on Tuesday to merge Universal Music Group with its investment fund under a plan to revive the...- Bill Ackman's Pershing Square proposes $64 billion merger deal with Universal Music GroupBill Ackman's Pershing Square has proposed a deal to merge Universal Music Group with its investment fund. The plan aims to revive the musi...
- SPARC enters pact with UCSF and Tiller Therapeutics for early stage oncology assetSun Pharma Advanced Research Company (SPARC) partners with Tiller Therapeutics. SPARC licenses its rights to a promising cancer treatment. ...
- SPARC seeks shareholders nod to raise up to Rs 1,800 crThe approval is being sought for raising funds for an aggregate consideration of up to Rs 1,800 crore or in equivalent foreign currency, SP...
- SPARC and Sun Pharma ink licensing pact for epilepsy drug"As per the agreement, SPARC will license Elepsia XRTM (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma ...
- SPARC, Sun Pharma drop on USFDA revocation of approvalShares of SPARC closed 2.62 per cent lower at Rs 375.80 after hitting the day's low of Rs 368.50 on the exchange. Parent Sum Pharma ended 3...
- SPARC to raise Rs 250 crore through rights issueSun Pharma Advanced Research Company was demerged from Sun Pharma as a pharma research and drug discovery company in 2007.
- Buy SPARC Ltd with a target of Rs 410: Ashwani Gujral"Buy SPARC Ltd with a target of Rs 410 and stop loss of Rs 385."
- Buy SPARC with a target of Rs 228: Mitesh Thacker"SPARC is a 'Buy' call with a target of Rs 228 and a stop loss of Rs 204."
- Sun Pharma Advanced Research Q1 loss at Rs 9.74 croreThe company had posted a net profit of Rs 9.51 crore during the same period of the previous fiscal, SPARC said in a statement.
- Buy SPARC with a target Rs 250: Mitesh Thacker"SPARC is a 'Buy' call with a target of Rs 250 and a stop loss of Rs 170."
- Buy SPARC with a target of Rs 200: Mitesh Thacker"SPARC Ltd is a 'buy' call with a target of Rs 200 and a stop loss of Rs 167."
- USFDA disapproves Sun Pharma unit's product in present formSun Pharma Advanced Research Company said the US health regulator has disapproved its New Drug Application for an anti-depressant product i...
- Buy SPARC with a target of Rs 190: Mitesh ThackerBuy SPARC with a target of Rs 190 and a stop loss of Rs 168: Mitesh Thacker.
- Buy SPARC with a target of Rs 190: Mitesh ThackerBuy SPARC with a target of Rs 190 and a stoploss of Rs 160: Mitesh Thacker.
- Buy SPARC with target price of Rs 175: Mitesh ThackerBuy SPARC with stop loss of Rs 157 for target of Rs 175.
- Drug discovery firm SPARC Q1 loss widens to Rs 18 croreThe company had posted a net loss of Rs 11.26 crore for the same period of 2011-12 fiscal, SPARC said in a statement.
- SPARC reports Q1 net loss at Rs 11.26 croreSun Pharma Advanced Research Company (SPARC) today posted a net loss of Rs 11.26 crore for the first quarter ended June 30, 2011.
- SPARC board approves rights issue, to raise up to Rs 200 crSun Pharma Advanced Research Company (SPARC) today said its board has approved rights issue to raise funds upto Rs 200 crore.
- HC approves Sun Pharma demergerSun Pharmaceuticals announced on Thursday that the Gujarat High Court had approved the company’s demerger of its ‘innovative’ research and ...
Load More
